CTLA4 and cancer: Antibody therapies called immune checkpoint inhibitors (ICIs) targeting molecules like CTLA-4, PD-1, and its ligand, PD-L1, are now commonly used in a wide variety of cancers and will be discussed in detail further on in this review.